Log In
BCIQ
Print this Print this
 

APX004

  Manage Alerts
Collapse Summary General Information
Company Apexigen Inc.
DescriptionHumanized mAb against VEGF receptor 2 (KDR/Flk-1; VEGFR-2)
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat angiogenic diseases; Treat cancer
Regulatory Designation
PartnerGansu Duyiwei Biotechnology Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/12/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today